ImmunoMind improves the design of T-cell therapies by precisely identifying T-cell subpopulations and their immune profile. ImmunoMind’s Augmented Intelligence platform guides translational and clinical research to improve the product’s quality, safety and efficacy with single-cell precision. The platform is based on proprietary single-cell multi-omics technologies to automatically evaluate cell differentiation, estimate exhaustion rate of subpopulations and identify off-tumor targets. UC Berkeley SkyDeck’20 Alumnus.